Robust EM continual reassessment method in oncology dose finding

DOI10.1198/JASA.2011.AP09476MaRDI QIDQ3111177zbMATHOpenAlexWikidataFDO

Authors Ying Yuan, Guosheng Yin

Publication date 18 January 2012

Published in Journal of the American Statistical Association (Search for Journal in Brave)

Full work available at URL http://europepmc.org/articles/pmc3286608

zbMATH Keywords

model selectionexpectation-maximization algorithmmissing datamaximum tolerated dosemodel averagingadaptive designlate-onset toxicity

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50)

Recommendations

• Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials
• Continual reassessment and related dose-finding designs
• A note on the robustness of the continual reassessment method
• A note on continual reassessment method
• Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity

Cited in

(10)

• Review of Statistical Treatment for Oncology Dose-Escalation Trial with Prolonged Evaluation Window or Fast Enrollment
• Adaptive clinical trial designs for phase I cancer studies
• A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes
• Biomarker-based precision dose finding for immunotherapy combined with radiotherapy
• Statistical frameworks for oncology dose-finding designs with late-onset toxicities: a review
• Application of gamma process to two-agent combinations with delayed toxicity
• Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial
• Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity
• Surv-CRM-12: a Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression
• BIPSE: a biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint

This page was built for publication: Robust EM continual reassessment method in oncology dose finding

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3111177)